Dixon Mitchell Investment Counsel Inc. Sells 94,102 Shares of Zoetis Inc. $ZTS

Dixon Mitchell Investment Counsel Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 99.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 541 shares of the company’s stock after selling 94,102 shares during the period. Dixon Mitchell Investment Counsel Inc.’s holdings in Zoetis were worth $68,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Global Wealth Strategies & Associates acquired a new position in Zoetis in the fourth quarter valued at approximately $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the fourth quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the third quarter valued at approximately $31,000. Holos Integrated Wealth LLC bought a new position in Zoetis in the fourth quarter valued at approximately $32,000. Finally, Elyxium Wealth LLC bought a new position in Zoetis in the fourth quarter valued at approximately $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. UBS Group reduced their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Friday, May 22nd. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $133.92.

Insiders Place Their Bets

In other news, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 11,650 shares of company stock worth $886,384 in the last quarter. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Stock Performance

Shares of ZTS opened at $79.51 on Friday. The firm has a 50-day moving average of $96.94 and a 200-day moving average of $114.22. Zoetis Inc. has a one year low of $72.38 and a one year high of $167.38. The company has a market cap of $33.33 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s payout ratio is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.